It’s no secret that pharmaceutical companies had a lot of regulatory issues to consider when marketing – and no marketing channel is more hotly discussed right now than the internet. From the highly anticipated guidelines on social media usage to the FTC’s proposed do-not-track list, there’s definitely a lot to keep track of these days.
Below are three regulatory issues that we here at 360 DI are monitoring closely.
- FDA Social Media Guidelines – The highly anticipated FDA guidelines on the use of social media for marketing and promotion of FDA-regulated medical products is definitely the 800LB gorilla in the room. These guidelines, which the FDA has said will be released by the end of the year, are expected to cover some of the biggest issues surrounding the use of social media among pharmaceutical companies – from the one-click rule to adverse events reporting. Ogilvy has already taken a position on one of those issues that was debated last November, with the 3′Cs Rule for Pharma Marketing. Stay tuned here as we will be sharing our point of view on these anticipated guidelines if and when they are released.
- DCC’s Brief to the FTC on Online Pharma Marketing – About two weeks ago, the Center for Digital Democracy filed a mammoth 144-page brief with the FTC challenging that agency to investigate online marketing activities by major health marketers – including pharmaceutical companies – as they relate to a variety of issues, including: collection of personal information, use of applications and widgets, disclosure of health blogger engagement, and even the disclosure of keywords being used in search engine marketing. You can peruse the huge PDF document here.
- FTC’s Proposed Do-Not-Track List – The idea of a “do-not list” is nothing new, as many of us have certainly taken advantage of the FTC’s highly popular Do-Not-Call list for telemarketing (myself included). This new proposal would essentially entegrate a feature into your web browser telling websites not to track what you do and where you go on their site. This proposal has major implications, not only for traditional online advertising, but also in the social media space; I do enjoy the “you might also want to follow” feature on the New Twitter. This one could get complicated. Check out the “Do Not Track” list proposal.
What other regulatory topics are you tracking related to pharmaceutical companies’ use of the internet? I wouldn’t want to miss any!
Image courtesy nessara.org
Posts
0 comments:
Post a Comment